This contract will provide for the production, scale-up, characterization and formulation of specific vaccine antigens and reagents as directed by the NIAID. In addition pilot lots of candidate vaccines will be produced under GLP/cGMPs appropriate for Phase I and Phase II human clinical trials.
IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
-
Activity
N01
-
Administering IC
AI
-
Application Type
-
Direct Cost Amount
-
Indirect Cost Amount
-
Total Cost
16181
-
Sub Project Total Cost
-
ARRA Funded
False
-
CFDA Code
855
-
Ed Inst. Type
-
Funding ICs
NIAID:16181\
-
Funding Mechanism
Contracts, Extramural
-
Study Section
-
Study Section Name